8-K: Tonix Licenses Non-Opioid Pain Drug TNX-4900 from Rutgers

Tonix Pharmaceuticals secured exclusive worldwide rights to TNX-4900, a selective Sigma-1 receptor antagonist with promising preclinical results for chronic neuropathic pain.

Summary

• Tonix Pharmaceuticals Holding Corp. licensed exclusive worldwide rights to TNX-4900 (formerly PW507) from Rutgers University.
• TNX-4900 is a highly selective small-molecule Sigma-1 receptor (S1R) antagonist designed using computer-aided and AI-driven approaches.
• Preclinical studies demonstrated TNX-4900's analgesic activity in multiple animal models of neuropathic pain, including diabetic and chemotherapy-induced pain.
• The compound showed significant and durable reductions in pain behaviors after acute and chronic dosing without evidence of tolerance or motor impairment.
• TNX-4900 binds the human Sigma-1 receptor with nanomolar affinity (Ki = 7.5 nM) and exhibits over 100-fold selectivity over the Sigma-2 receptor.
• It possesses high blood-brain barrier penetration and favorable ADME properties, including approximately 28% oral bioavailability.
• Tonix plans to advance TNX-4900 through expanded pharmacokinetic, formulation, and safety studies to support an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA).

Sentiment

Score: 8

Explanation: The announcement is highly positive, indicating a significant expansion of Tonix's pipeline with a promising, potentially best-in-class non-opioid analgesic candidate for a high-need area. The preclinical data are strong, and the company's existing expertise in non-opioid pain management adds credibility.

Positives

• Acquisition of a promising, highly selective non-opioid analgesic candidate, TNX-4900, addresses a significant unmet medical need for chronic neuropathic pain.
• Preclinical data for TNX-4900 show robust analgesic efficacy in multiple pain models and an encouraging safety profile, including no evidence of tolerance or motor impairment.
• TNX-4900's high selectivity for the Sigma-1 receptor (over 100-fold compared to Sigma-2) and favorable pharmacokinetic properties (high blood-brain barrier penetration, oral bioavailability) suggest a strong therapeutic profile.
• Tonix's existing experience with an FDA-approved non-opioid analgesic (TONMYA) positions the company well to develop TNX-4900, with management believing it has 'potential to be best-in-class'.

Risks

• The development of TNX-4900 is subject to significant risks inherent in pharmaceutical development, including the failure to successfully complete clinical trials, obtain FDA clearances or approvals, and commercialize new products.
• There is a need for additional financing to support ongoing and future product development programs.
• Uncertainties exist regarding patent protection and potential litigation.
• The company faces substantial competition in the pharmaceutical industry.
• The efficacy and safety of TNX-4900 have not yet been established in humans and it has not been approved for any indication.

Future Outlook

Tonix plans to advance TNX-4900 through expanded pharmacokinetic, formulation, and safety studies to support an Investigational New Drug (IND) application with the FDA. Additionally, TNX-2900 for Prader-Willi syndrome is expected to start a potential pivotal Phase 2 study in 2026.

Management Comments

• Seth Lederman, M.D., President and CEO of Tonix Pharmaceuticals, stated, "With our extensive experience studying and developing an FDA approved non-opioid analgesic we are well-positioned to oversee this new development program. We believe TNX-4900 has the potential to be best-in-class."
• Dr. Youyi Peng, co-inventor of TNX-4900 and consultant to Tonix, noted, "We used computer-aided and AI-driven approaches to design this new class of selective Sigma-1 receptor antagonists. TNX-4900 showed robust analgesic efficacy in multiple pain models and an encouraging safety profile, supporting its potential as a new non-opioid approach to treating neuropathic pain."
• Dr. William Welsh, Distinguished Professor at Rutgers Robert Wood Johnson Medical School, commented, "Our foundational research into TNX-4900 represents an important step toward developing non-opioid solutions for chronic pain. We are pleased to see this innovation progress toward potential clinical application, which could address a critical need for safer pain management options."

Industry Context

The licensing of TNX-4900 positions Tonix Pharmaceuticals to further capitalize on the growing demand for non-opioid pain management solutions, a critical area given the ongoing opioid crisis. Tonix already markets TONMYA, an FDA-approved non-opioid analgesic for fibromyalgia, providing the company with relevant experience and infrastructure in this therapeutic space. The focus on a highly selective Sigma-1 receptor antagonist aligns with broader industry efforts to develop novel mechanisms for pain relief with improved safety profiles.

Comparison to Industry Standards

• The filing highlights TNX-4900's "potential to be best-in-class" among non-opioid analgesics, citing its high selectivity for the Sigma-1 receptor (>100-fold over Sigma-2) and demonstrated analgesic efficacy in multiple preclinical neuropathic pain models (diabetic and chemotherapy-induced) without evidence of tolerance or motor impairment.
• While specific comparable companies or projects are not detailed in the filing, the context is the critical need for safer, non-addictive alternatives to opioids and other existing treatments for chronic neuropathic pain, which often have significant side effects or limited efficacy.
• Tonix's prior success with TONMYA, an FDA-approved non-opioid analgesic for fibromyalgia, provides a benchmark for its capabilities in developing and commercializing non-opioid pain therapies.

Stakeholder Impact

• Shareholders: Potential for increased long-term value through pipeline expansion into a high-demand therapeutic area.
• Patients: Potential for a new, non-opioid treatment option for chronic neuropathic pain, addressing a significant unmet medical need.
• Rutgers University: Successful licensing of intellectual property, validating their research and potentially leading to future collaborations or royalties.
• Employees: Potential for new development programs and increased R&D activity.

Next Steps

• Advance TNX-4900 through expanded pharmacokinetic, formulation, and safety studies.
• Prepare to support an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for TNX-4900.
• Initiate a potential pivotal Phase 2 study for TNX-2900 (Prader-Willi syndrome) in 2026.

Key Dates

Recommendation

The licensing of TNX-4900 is a positive strategic move, expanding Tonix's pipeline with a promising preclinical asset in the high-demand non-opioid pain market. The strong preclinical data and Tonix's existing expertise in this area are encouraging. However, TNX-4900 is still in early-stage development, requiring significant further investment and successful navigation of clinical trials and regulatory approvals. Given the early stage of this specific asset, a 'hold' recommendation is prudent, acknowledging the long-term potential while recognizing the inherent risks and timelines associated with drug development. Investors should monitor progress through IND-enabling studies and subsequent clinical trials.

Keywords

Neuropathic pain, Sigma-1 receptor antagonist, Non-opioid analgesic, Drug licensing, Biotechnology, Pain management, Preclinical development, TNX-4900, Tonix Pharmaceuticals, Rutgers University